The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $697,000 grant to a research project using preclinical models to study early Parkinson’s disease linked to mutations in the PINK1 gene. Cynthia Kelm-Nelson, PhD, a department of surgery senior scientist, will lead the three-year project…
A new study suggests that simple, targeted strategies, from using telehealth to standardizing patient referrals, could help more people with Parkinson’s disease get the specialized care they urgently need. With U.S. cases expected to double by 2040, researchers warn that existing healthcare inequities will worsen without immediate action. “Research…
People with metabolic syndrome, a cluster of metabolism-related abnormalities — like a larger waist circumference, high blood sugar, and abnormal blood levels of fatty molecules — may have a higher risk of Parkinson’s disease, according to the findings of a new study by an international team of researchers. Having…
Parkinson’s disease patients who receive donor-derived brain stem cell therapy may be able to avoid potent immunosuppressant drugs without showing signs of rejection, a study in Japan suggested. The Phase 1/2 trial (jRCT2090220384) tested transplants of dopamine-producing precursor cells made from induced pluripotent stem cells (iPSCs) — stem…
Noninvasively stimulating a nerve in the leg using Stimvia‘s URIS device is feasible, safe, and may help reduce motor symptoms and improve quality of life in people with Parkinson’s disease, according to new data from a pilot study. Indeed, among the small number of patients with tremor in…
The Parkinson’s Foundation has launched a pilot program it hopes will make it easier for Parkinson’s disease patients who carry specific disease-related genetic variants to enroll in clinical trials testing targeted experimental treatments. The new program, dubbed PD Trial Navigator, is designed to help meet a central goal of…
Stanford University researchers developed a simple, portable device that allows Parkinson’s disease patients to monitor their motor symptoms remotely, in real time, providing their doctors with updated information that can be used to guide treatment decisions. Patients tap alternating fingers for 30 seconds on the two-lever device, called KeyDuo, which…
An oral anti-inflammatory therapy for Parkinson’s disease developed using artificial intelligence (AI) may be nearing clinical trials. Insilico Medicine said it plans to seek clearance later this year from the U.S. Food and Drug Administration (FDA) to advance the therapy, ISM8969, into human trials. The company said its…
Herantis Pharma announced that its Phase 1b clinical trial evaluating the safety and preliminary efficacy of HER-096, a potential disease-modifying therapy for Parkinson’s disease, has hit a key milestone: All dosing regimens and follow-up clinic visits have been completed. Top-line results from the trial (NCT06659562, EUCT2024-512532-30-00) —…
OM1 has expanded a real-world dataset of people with neurological conditions, including Parkinson’s disease, adding health records and clinical notes for 500,000 more people. “Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” Carl Marci, MD,…
Get regular updates to your inbox.
